Abstract
(-)-Stepholidine (SPD), a natural product isolated from the Chinese herb Stephania, possesses dopamine (DA) D1 partial agonistic and D2 antagonistic properties in the nigrostriatal and mesocorticolimbic DAergic pathways. These unique dual effects have suggested that SPD can effectively restore previously imbalanced functional linkage between D1 and D2 receptors under schizophrenic conditions, in which, SPD improves both the negative and positive symptoms of schizophrenia. SPD also relieves the motor symptoms of Parkinsons disease (PD) when co-administered with Levodopa. Furthermore, SPD exhibits neuroprotective effects through an antioxidative mechanism and slows down the progression of neuronal degeneration in the substantia nigra (SN) of PD patients and/or animal models. Therefore, SPD is a novel, natural compound with potentially therapeutic roles in the treatment of schizophrenia and/or PD.
Keywords: Stepholidine, dopamine D1 receptor, dopamine D2 receptor, schizophrenia, Parkinson's disease
Current Neuropharmacology
Title: The Neuropharmacology of (-)-Stepholidine and its Potential Applications
Volume: 5 Issue: 4
Author(s): Kechun Yang, Guozhang Jin and Jie Wu
Affiliation:
Keywords: Stepholidine, dopamine D1 receptor, dopamine D2 receptor, schizophrenia, Parkinson's disease
Abstract: (-)-Stepholidine (SPD), a natural product isolated from the Chinese herb Stephania, possesses dopamine (DA) D1 partial agonistic and D2 antagonistic properties in the nigrostriatal and mesocorticolimbic DAergic pathways. These unique dual effects have suggested that SPD can effectively restore previously imbalanced functional linkage between D1 and D2 receptors under schizophrenic conditions, in which, SPD improves both the negative and positive symptoms of schizophrenia. SPD also relieves the motor symptoms of Parkinsons disease (PD) when co-administered with Levodopa. Furthermore, SPD exhibits neuroprotective effects through an antioxidative mechanism and slows down the progression of neuronal degeneration in the substantia nigra (SN) of PD patients and/or animal models. Therefore, SPD is a novel, natural compound with potentially therapeutic roles in the treatment of schizophrenia and/or PD.
Export Options
About this article
Cite this article as:
Yang Kechun, Jin Guozhang and Wu Jie, The Neuropharmacology of (-)-Stepholidine and its Potential Applications, Current Neuropharmacology 2007; 5 (4) . https://dx.doi.org/10.2174/157015907782793649
DOI https://dx.doi.org/10.2174/157015907782793649 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Targeted D4 Dopamine Receptors: Implications for Drug Discovery and Therapeutic Development
Current Drug Targets Concepts for Biologically Active Peptides
Current Pharmaceutical Design Synthesis of L-Dopa Modifier L-Dopa-L-His and its Interaction with DNA
Letters in Organic Chemistry The Role of Melatonin in the Immuno-Neuro-Psychology of Mental Disorders
Recent Patents on CNS Drug Discovery (Discontinued) Antipsychotic-like Effects of Cannabidiol and Rimonabant: Systematic Review of Animal and Human Studies
Current Pharmaceutical Design <i>Withania somnifera</i> in Neurological Disorders: Ethnopharmacological Evidence, Mechanism of Action and its Progress in Delivery Systems
Current Drug Metabolism Pediatric Catatonia: Updating An Old Syndrome in Young People
Current Psychiatry Reviews Wnt Signaling Pathway in Schizophrenia
CNS & Neurological Disorders - Drug Targets Prevalence of Pre-Existing Risk Factors for Adverse Events Associated with Atypical Antipsychotics Among Commercially Insured and Medicaid Insured Patients Newly Initiating Atypical Antipsychotics
Current Drug Safety Will it Ever Become Possible to Prevent Dopaminergic Neuronal Degeneration?
CNS & Neurological Disorders - Drug Targets Classical Neurotransmitters and Neuropeptides Involved in Schizophrenia: How to Choose the Appropriate Antipsychotic Drug?
Current Drug Therapy Deprescribing Antipsychotic Medications in Psychotic Disorders: How and Why?
Current Psychiatry Reviews Artificial Neural Network (ANN) Based Modelling for D1 Like and D2 Like Dopamine Receptor Affinity and Selectivity
Medicinal Chemistry Leukopenia Associated with Risperidone Treatment
Current Drug Safety Organometallic Complexes: New Tools for Chemotherapy
Current Medicinal Chemistry Current Therapeutic Options for Alzheimers Disease
Current Genomics Caffeine; the Forgotten Potential for Parkinson's Disease
CNS & Neurological Disorders - Drug Targets Modulation Effects of Piracetam and Ginkgo biloba on the Cognitive and Working Memory Functions: Psychometric Study
Current Psychopharmacology Cannabidiol and Sodium Nitroprusside: Two Novel Neuromodulatory Pharmacological Interventions to Treat and Prevent Psychosis
CNS & Neurological Disorders - Drug Targets An Introduction to the Nutrition and Metabolism of Choline
Central Nervous System Agents in Medicinal Chemistry